Scientific evidence and research highlights
Pre-clinical testing conducted on Rejwin, evaluated across multiple cell lines and animal models.
In-vitro broad-spectrum cytotoxicity (MTT, LDH and TB assays)
Rejwin exhibited selective cytotoxic activity against various cancer cell lines, while demonstrating significantly lower toxicity toward normal cell lines:
| Cell line | Organism | Tissue source | Disease | IC50 (μg/mL) |
|---|---|---|---|---|
| A375 | Human | Skin | Melanoma | 13.2 |
| B16F10 | Mouse | Skin | Melanoma | 11.2 |
| HeLa | Human | Cervix | Cervical Adenocarcinoma | 8.2 |
| A549 | Human | Lung | Lung Adenocarcinoma | 8.5 |
| MDA-MB-231 | Human | Mammary Gland | Breast Adenocarcinoma (TNBC) | 8.9 |
| MDA-MB-468 | Human | Mammary Gland | Breast Adenocarcinoma | 9.8 |
| MCF7 | Human | Mammary Gland | Breast Adenocarcinoma | 9.1 |
| CaCo2 | Human | Colon | Colorectal Adenocarcinoma | 12.8 |
| HCT15 | Human | Colon | Colorectal Carcinoma | 11.3 |
| HCT116 | Human | Colon | Colorectal Adenocarcinoma | 12.9 |
| HT29 | Human | Colon | Colorectal Adenocarcinoma | 13.9 |
| HepG2 | Human | Liver | Hepatocellular Carcinoma | 8.4 |
| PA01 | Human | Ovary | Teratocarcinoma | 9.8 |
| U87 | Human | Brain | Glioblastoma | 15.1 |
| Beas 2B | Human | Normal Lung | None (normal cells) | 52.8 (Safe) |
| NIH3T3 | Mouse | Normal Embryo | None (normal cells) | 45.0 (Safe) |
| Raw 264.7 | Mouse | Normal Macrophage | None (normal cells) | 29.5 (Safe) |
| L132 | Human | Normal Lung | None (normal cells) | 56.0 (Safe) |
| HaCat | Human | Normal Skin | None (normal cells) | 65.0 (Safe) |
The high IC50 values in normal non-cancerous lines (45.0 - 65.0μg/mL) compared to low values in malignant lines (8.2 - 15.1μg/mL) confirm high selectivity towards tumour cells.
Key In-Vivo efficacy studies
Ascitic Tumour Model (EAC)
Treatment at 25mg/kg and 50mg/kg body weight significantly reduced ascites fluid volume, lowered cell density, and improved overall survival rates.
Solid Tumour Model (EAC)
Led to dose-dependent tumour regression, significant reduction in tumour mass/weight, and increased survival rates.
Xenograft & Transgenic Disease Models
Demonstrated significant regression in Lung Adenocarcinoma (LLC) and Hepatocellular Carcinoma (DEN-induced HCC) animal models.
Micro vessel Suppression (CAM & Matrigel Assays)
Visibly reduced peritoneal micro vessel density and rVEGF165-induced neovascularization, confirming strong anti-angiogenic activity In vivo.
Comprehensive safety and toxicology profile
Acute Oral Toxicity Test (2000mg/kg)
No mortality, behavioural abnormalities, or macroscopic organ damage were observed over 14 days.
Repeated Toxicity Study
Showed no adverse changes in body weight, food consumption, or water intake.
Haematology & Biomarkers
SGOT, SGPT (liver function), Serum Creatinine and Urea (renal function) levels remained within normal ranges.
Histopathology
Detailed microscopic examinations of organ sections (liver, lung, spleen, kidney, colon, intestine, brain, stomach, tongue, testis) showed normal cellular architecture without structural damage.
For more research work